# US 2012/0252797 A1 · Isoxazole Compounds As Inhibitors Of Heat Shock Proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252797 A1
- Document ID: US20120252797A1
- Status: Published application
- Kind: A1
- Application number: 13/525,409
- Filed: 2012-06-18
- Published: 2012-10-04
- Earliest claimed: 2003-02-11
- Assignees: Vernalis (Cambridge) Limited; The Institute of Cancer Research; Cancer Research Technology Limited
- Inventors: Martin James Drysdale; Brian William Dymock; Harry Finch; Paul Webb; Edward McDonald; Karen Elizabeth James; Kwai Ming Cheung; Thomas Peter Matthews
- Web page: https://patentgrep.com/patent/US20120252797A1

## CPC

- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61K 31/42: Oxazoles
- A61K 31/422: not condensed and containing further heterocyclic rings
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/06: Antiasthmatics
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 261/08: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 261/10: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/10: linked by a carbon chain containing aromatic rings
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 495/04: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Isoxazoles of formula (A) or (B) wherein R1 is a group of formula (IB) The isoxazoles are inhibitors of HSP90 activity, and useful for the treatment of, for example, cancers.

## Claims

### Claim 1

A compound of formula (A) or (B) or a salt or N-oxide thereof:
wherein
R1 is a group of formula (IB)
wherein:
R represents one or more optional substituents selected from (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy, hydroxy, (C1-C6)alkyl, halo, trifluoromethyl, trifluoromethoxy, oxo, phenyl, —COOH, —COORA, —CORA—, wherein RA is a (C1-C6)alkyl group,
Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals,
p, r and s are independently 0 or 1,
Z is —O—, —S—, —(C═O)—, —(C═S)—, —SO2—, —C(═O)O—, —C(═O)NRA—, —C(═S)NRA—, —SO2NRA—, —NRAC(═O)—, —NRASO2— or —NRA— wherein RA is hydrogen or C1-C6 alkyl, and
Q is hydrogen or an optionally substituted phenyl or pyridinyl radical;
R2 is (i) a group of formula (IB):
—Ar1-(Alk1)p-(Z)r-(Alk2)s-Q1 (IB)
wherein:
Ar1 is an optionally substituted aryl or heteroaryl radical, and
Alk1, Alk2, p, r, s, Z, and RA are as defined in relation to R1;
Q1 is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; or
(ii) a carboxamide radical; or
(iii) a non aromatic carbocyclic or heterocyclic ring wherein a ring carbon is optionally substituted, and/or a ring nitrogen is optionally substituted by a group of formula -(Alk1)p-(Z)r-(Alk2)s-Q1, wherein Alk1, Alk2, Z, p, r and s are as defined above in relation to group of formula (IA) and Q1 is as defined above in relation to group of formula (IB); and
R3 is carboxyl, carboxamide, or carboxyl ester group,
wherein the term optionally substituted means substituted with up to four substituents selected from (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy, hydroxy(C1-C6)alkyl, mercapto, mercapto(C1-C6)alkyl, (C1-C6)alkylthio, halo, trifluoromethyl, trifluoromethoxy, nitro, nitrile (—CN), oxo, phenyl, —COON, —COORA, —CORA, SO2RA, —CONH2, —SO2NH2, —CONHRA, —SO2NHRA, —CONRARB, —SO2NRARB, —NH2, —NHRA, —NRARB, —OCONH2, —OCONHRA, —OCONRARB, —NHCORA, —NHCOORA, —NRBCOORA, —NHSO2ORA, —NRBSO2OH, —NRBSO2ORA, —NHCONH2, —NRACONH2, —NHCONHRB, —NRACONHRB, —NHCONRARB, or —NRACONRARB wherein RA and RB are independently a (C1-C6)alkyl group.

### Claim 2 (depends on 1)

A compound as claimed in claim 1 wherein R3 is a carboxamide group.

### Claim 3 (depends on 1)

A compound as claimed in claim 1 wherein the compound is one of formula (A).

### Claim 4 (depends on 1)

A compound as claimed in claim 1 wherein the ring carbon atom adjacent the hydroxyl group in radical (IB) is unsubstituted.

### Claim 5 (depends on 1)

A compound as claimed in claim 1 wherein, in R1, each of p, r and s is 0, and Q is hydrogen.

### Claim 6 (depends on 1)

A compound as claimed in claim 1 wherein R1 is optionally substituted phenyl.

### Claim 7 (depends on 6)

A compound as claimed in claim 6 wherein R1 is 2-hydroxyphenyl, optionally further substituted by one or more of hydroxy, methyl, ethyl, methoxy, ethoxy, chloro, or bromo.

### Claim 8 (depends on 6)

A compound as claimed in claim 6 wherein R1 is 2,4-dihydroxyphenyl, substituted in the 5-position by a methyl, ethyl, isopropyl, isobutyl, tert-butyl, chloro, or bromo.

### Claim 9 (depends on 7)

A compound as claimed in claim 7 wherein the hydroxyl groups in R1 are protected by groups which are cleaved in the body to release the hydroxyl groups.

### Claim 10 (depends on 9)

A compound as claimed in claim 9 wherein the protecting groups are alkylcarbonyloxy or alkylaminocarbonyloxy groups.

### Claim 11 (depends on 9)

A compound as claimed in claim 9 wherein the protecting groups are methylcarbonyloxy, or isopropylamino-carbonyloxy.

### Claim 12 (depends on 1)

A compound as claimed in claim 1 wherein, in R1, p, r and s are each 0, and Q is an optionally substituted phenyl or pyridyl ring.

### Claim 13 (depends on 12)

A compound as claimed in claim 12 wherein Q is an optionally substituted phenyl ring.

### Claim 14 (depends on 1)

A compound as claimed in claim 1 wherein, in R1, p and/or s are each 1 and r is 0.

### Claim 15 (depends on 1)

A compound as claimed in claim 1 wherein, in R1, each of p, r, and s is 1.

### Claim 16 (depends on 1)

A compound as claimed in claim 1 wherein, in R1, p and s are each 0 and r is 1.

### Claim 17 (depends on 16)

A compound as claimed in claim 16 wherein R2 is optionally substituted 2-, 3, or 4-pyridyl, 2- or 3-furanyl, 2- or 3-thienyl, or thiazolyl.

### Claim 18 (depends on 17)

A compound as claimed in claim 17 wherein optional substituents present in R2 are selected from methoxy, ethoxy, methylenedioxy, ethylenedioxy, fluoro, chloro, bromo, and trifluoromethyl.

### Claim 19 (depends on 16)

A compound as claimed in claim 16 wherein R2 is phenyl substituted in the 4 position by methoxy, ethoxy, fluoro, chloro, bromo, piperazinyl, N-methylpiperazinyl, or piperidinyl.

### Claim 20 (depends on 1)

A compound as claimed in claim 1 wherein R2 has the partial structure:
wherein the substituted amino group —NR10R11 is selected from morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, ethylamino, isopropylamino, diethylamino, cyclohexylamino, cyclopentylamino, methoxyethylamino, piperidin-4-yl, N-acetylpiperazinyl, methylsulfonylamino, thiomorpholinyl, thiomorpholinyldioxide, 4-hydroxyethylpiperidinyl, and 4-hydroxypiperidinyl.

### Claim 21 (depends on 1)

A compound as claimed in claim 1 wherein R2 is a carboxamide group of formula —CONRB(Alk)nRA wherein
Alk is an optionally substituted divalent alkylene, alkenylene or alkynylene radical,
n is 0 or 1,
RB is hydrogen or a C1-C6 alkyl or C2-C6 alkenyl group,
RA is hydroxy or optionally substituted carbocyclic,
or RA and RB taken together with the nitrogen to which they are attached form an N-heterocyclic ring which may optionally contain one or more additional hetero atoms selected from O, S and N, and which may optionally be substituted on one or more ring C or N atoms.

### Claim 22 (depends on 1, 21)

A compound as claimed in claim 1 wherein R3 is a carboxamide group —CONRB(Alk)nRA as defined in claim 21.

### Claim 23 (depends on 1)

A compound as claimed in claim 1 wherein R3 is ethylaminocarbonyl or isopropylaminocarbonyl.

### Claim 24 (depends on 1)

A compound as claimed in claim 1 having formula (ID) or the formula B regioisomer (ID1) thereof having the formula (ID1)
wherein each R independently represents an optional substituent and R3 represents a carboxamide group.

### Claim 25 (depends on 1)

A compound as claimed in claim 1 having formula (IE)
or the formula B regioisomer thereof having the formula (IE1)
wherein R3 represents a carboxamide group; R9 represents —CH2NR10R11 or —NR10R11 wherein the substituted amino group —NR10R11 is selected from morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, ethylamino, isopropylamino, diethylamino, cyclohexylamino, cyclopentylamino, methoxyethylamino, piperidin-4-yl, N-acetylpiperazinyl, methylsulfonylamino, thiomorpholinyl, thiomorpholinyldioxide, 4-hydroxyethylpiperidinyl, and 4-hydroxypiperidinyl; and R8 represents an optional substituent.

### Claim 26 (depends on 25)

A compound as claimed in claim 25 wherein R3 is ethylaminocarbonyl CH3CH2NHC(═O)—, or isopropylaminocarbonyl (CH3)2CHNHC(═O)—; the substituted amino group —NR10R11 in R9 is morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, ethylamino, isopropylamino, diethylamino, cyclohexylamino, cyclopentylamino, methoxyethylamino, piperidin-4-yl, N-acetylpiperazinyl, N-methylpiperazinyl, methylsulfonylamino, thiomorpholinyl, thiomorpholinyldioxide, 4-hydroxyethylpiperidinyl, or 4-hydroxypiperidinyl); and R8 is ethyl, isopropyl, bromo, or chloro.

### Claim 27 (depends on 1)

A compound as claimed in claim 1 selected from the group consisting of:
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide,
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-piperidin-1-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide,
4-(4-Diethylaminomethyl-phenyl)-5-(2,4-dihydroxy-5-isopropyl-phenyl)-isoxazole-3-carboxylic acid ethylamide,
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-isoxazole-3-carboxylic acid ethylamide,
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-ethylaminomethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide,
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-[4-(isopropylamino-methyl)-phenyl]-isoxazole-3-carboxylic acid ethylamide,
4-(4-Cyclohexylaminomethyl-phenyl)-5-(2,4-dihydroxy-5-isopropyl-phenyl)-isoxazole-3-carboxylic acid ethylamide,
4-[4-(tert-Butylamino-methyl)-phenyl]-5-(2,4-dihydroxy-5-isopropyl-phenyl)-isoxazole-3-carboxylic acid ethylamide,
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-{4-[(2-methoxy-ethylamino)-methyl]-phenyl}-isoxazole-3-carboxylic acid ethylamide,
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid isopropylamide,
5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-isoxazole-3-carboxylic acid isopropylamide,
5-(5-tert-Butyl-2,4-dihydroxy-phenyl)-4-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-isoxazole-3-carboxylic acid ethylamide,
5-(5-tert-Butyl-2,4-dihydroxy-phenyl)-4-(4-piperidin-1-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide,
5-(2,4-Dihydroxy-5-isobutylisopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide,
5-(2,4-Dihydroxy-5-isobutyl-phenyl)-4-(4-piperidin-1-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide,
5-(5-tert-Butyl-2,4-dihydroxy-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide,
5-(5-tert-Butyl-2,4-dihydroxy-phenyl)-4-(4-diethylaminomethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide,
3-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-5-carboxylic acid ethylamide,
4-(4-Diethylaminomethyl-phenyl)-5-(4,6-dihydroxy-2′-methyl-biphenyl-3-yl)-isoxazole-3-carboxylic acid ethylamide,
4-(4-Diethylaminomethyl-phenyl)-5-(4′-fluoro-4,6-dihydroxy-biphenyl-3-yl)-isoxazole-3-carboxylic acid ethylamide,
4-(4-Diethylaminomethyl-phenyl)-5-(4,6-dihydroxy-biphenyl-3-yl)-isoxazole-3-carboxylic acid ethylamide,
5-(2′-Fluoro-4,6-dihydroxy-biphenyl-3-yl)-4-(4-pyrrolidin-1-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide,
5-(4,6-Dihydroxy-biphenyl-3-yl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide,
5-(2,4-Dihydroxy-5-phenethyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide,
5-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-piperidin-1-ylmethyl-phenyl)-isoxazole-3-carboxylic acid isopropylamide,
4-(4-Diethylaminomethyl-phenyl)-5-(5-ethyl-2,4-dihydroxy-phenyl)-isoxazole-3-carboxylic acid ethylamide,
5-(5-Ethyl-2,4-dihydroxy-phenyl)-4-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-isoxazole-3-carboxylic acid ethylamide,
5-(5-Ethyl-2,4-dihydroxy-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide,
5-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-diethylaminomethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide,
5-(5-Chloro-2,4-dihydroxy-phenyl)-4-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-isoxazole-3-carboxylic acid ethylamide, and
5-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide,
and or a salt thereof.

### Claim 28 (depends on 1)

A pharmaceutical composition comprising a compound as claimed in claim 1, together with a pharmaceutically acceptable carrier.

### Claim 29 (depends on 28)

A pharmaceutical composition as claimed in claim 28 in the form of a solution or suspension of the compound in a sterile, physiologically acceptable carrier.

### Claim 30 (depends on 28)

A pharmaceutical composition as claimed in claim 28 in the form of a solution or suspension of the compound in sterile aqueous saline.

### Claim 31

5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-iso-xazole-3-carboxylic acid ethylamide, or a salt thereof.

### Claim 32 (depends on 31)

A pharmaceutical composition comprising a compound as claimed in claim 31, together with a pharmaceutically acceptable carrier.

### Claim 33 (depends on 32)

A pharmaceutical composition as claimed in claim 32 in the form of a solution or suspension of the compound in a sterile, physiologically acceptable carrier.

### Claim 34 (depends on 32)

A pharmaceutical composition as claimed in claim 32 in the form of a solution or suspension of the compound in sterile aqueous saline.
